Pregabalin is an anticonvulsant drug used to treat neuropathic pain conditions and fibromyalgia, and for the treatment of partial onset seizures in combination with other anticonvulsants.

Brand Names
Generic Name
DrugBank Accession Number

Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter.13 It may be used to manage neuropathic pain, postherpetic neuralgia, and fibromyalgia among other conditions.20 Although as per the FDA Label the mechanism of action has not been definitively characterized, there is evidence that pregabalin exerts its effects by binding to the α2δ subunit of voltage-dependent calcium channels.20,22 Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release).21,22 It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.4

Small Molecule
Approved, Investigational
Average: 159.2261
Monoisotopic: 159.125928793
Chemical Formula
  • (S)-3-Isobutyl GABA
  • 3-Isobutyl GABA
  • Pregabalin
  • Pregabalina
External IDs
  • CI 1008
  • CI-1008
  • PD-144723
  • YNP-1807



Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and as adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older.22

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Management ofDiabetic peripheral neuropathic pain•••••••••••••••••••• ••••••••• ••••••• •••••••• •••••••
Used in combination to manageEpilepsiesCombination Product in combination with: Mecobalamin (DB03614)••••••••••••••••••• ••• ••••••••••• •• •••••••••••••••• •••••••••• ••••••••••••••• •••• ••••••
Management ofFibromyalgia•••••••••••••••••••• ••••••••
Used in combination to manageFibromyalgiaCombination Product in combination with: Mecobalamin (DB03614)•••••••••••••• •••••••••••••••• •••••••••• ••••••••• ••••••• ••• ••••••••••••••••• •••• ••••••
Used in combination for symptomatic treatment ofFibromyalgiaCombination Product in combination with: Cyanocobalamin (DB00115)••••••••••••••••••• ••• ••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more

Although the structure of pregabalin is similar to gamma-aminobutyric acid (GABA), it does not bind to GABA receptors.6,20 Instead, it binds the alpha2-delta subunit of presynaptic voltage-gated calcium channels in the central nervous system.6,20 Pregabalin does not modulate dopamine receptors, serotonin receptors, opiate receptors, sodium channels or cyclooxygenase activity.20

Mechanism of action

Although the mechanism of action has not been fully elucidated, studies involving structurally related drugs suggest that presynaptic binding of pregabalin to voltage-gated calcium channels is key to the antiseizure and antinociceptive effects observed in animal models.22

By binding presynaptically to the alpha2-delta subunit of voltage-gated calcium channels in the central nervous system, pregabalin modulates the release of several excitatory neurotransmitters including glutamate, substance-P, norepinephrine, and calcitonin gene related peptide.6 In addition, pregabalin prevents the alpha2-delta subunit from being trafficked from the dorsal root ganglia to the spinal dorsal horn, which may also contribute to the mechanism of action.15

Although pregabalin is a structural derivative of the inhibitory neurotransmitter gamma-aminobutyric acid (GABA), it does not bind directly to GABA or benzodiazepine receptors.8

AVoltage-dependent calcium channel subunit alpha-2/delta-1Not AvailableHumans

After oral dosing administered in the fasted state, pregabalin absorption is rapid, and extensive.8 Pregabalin oral bioavailability is reported to be ≥90% regardless of the dose.8 Cmax is attained within 1.5 hours after single or multiple doses, and steady state is attained within 24-48 hours with repeated administration.8,22 Both Cmax and AUC appear to be dose proportional.8

Food decreases the rate of pregabalin absorption and as a result, lowers the Cmax by an estimated 25-30% and increases the Tmax to approximately 3 hours.22 However, the effect of food does not appear to impact the total absorption of pregabalin in a way that is clinically relevant. As a result, pregabalin can be administered with or without food.22

Volume of distribution

After oral administration of pregabalin, the reported apparent volume of distribution is roughly 0.5 L/kg.22

Although pregabalin is not very lipophilic, it is able to cross the blood brain barrier(BBB).16 System L transporters facilitate the transport of large amino acids across the BBB and it has been confirmed that pregabalin is a substrate.22,16 This information suggests that system L transporters are responsible for pregabalin uptake into the BBB.16

In rat models, pregabalin has been shown to cross the placenta.22

Protein binding

Pregabalin is not plasma protein bound.8,22


Less than 2% of pregabalin is metabolized and it is excreted virtually unchanged in the urine.8,22

Hover over products below to view reaction partners

Route of elimination

Pregabalin is almost exclusively eliminated in the urine.17,18

Further, based on preclinical studies, pregabalin does not appear to undergo racemization to the R enantiomer in the body.11


The elimination half life of pregabalin is 6.3 hours.22


In young healthy subjects the mean renal clearance is estimated to be 67.0 to 80.9 mL mL/min.22 Given pregabalin's lack of plasma protein binding, this clearance rate suggests that renal tubular reabsorption is involved.22

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample

In a systematic review that included 38 randomized controlled trials, there were 20 identified adverse effects that were significantly associated with pregabalin, most of which involve the central nervous system and cognition. The identified adverse effects include vertigo, dizziness, balance disorder, incoordination, ataxia, blurred vision, diplopia, amblyopia, somnolence, confusional state, tremor, disturbance in attention, abnormal thinking, asthenia, fatigue, euphoria, edema, peripheral edema, dry mouth, and constipation 14.

The most common symptoms of pregabalin toxicity (dose range includes 800 mg/day and single doses up to 11,500 mg) include somnolence, confusion, restlessness, agitation, depression, affective disorder and seizures.23

Since there is no antidote for pregabalin overdose, patients should receive general supportive care. If appropriate, gastric lavage or emesis may help eliminate unabsorbed pregabalin (healthcare providers should take standard precautions to maintain the airway).23

Pregabalin pharmacokinetic properties suggest that extra-corporeal elimination methods including haemodialysis, may be useful in situations of severe toxicity.19 However, there are cases where patients have presented with very high serum levels of pregabalin and have been successfully managed with supportive care alone.19

Not Available
Pharmacogenomic Effects/ADRs
Not Available


Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
1,2-BenzodiazepineThe therapeutic efficacy of 1,2-Benzodiazepine can be increased when used in combination with Pregabalin.
AbacavirPregabalin may decrease the excretion rate of Abacavir which could result in a higher serum level.
AcarboseThe risk or severity of hypoglycemia can be increased when Pregabalin is combined with Acarbose.
AcebutololPregabalin may increase the bradycardic activities of Acebutolol.
AceclofenacAceclofenac may decrease the excretion rate of Pregabalin which could result in a higher serum level.
Food Interactions
  • Avoid alcohol. Alcohol may increase CNS effects.
  • Take with or without food. Food alters drug absorption, but not to a clinically significant extent.


Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Images
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Act PregabalinCapsule100 mgOralActavis Pharma CompanyNot applicableNot applicableCanada flag
Act PregabalinCapsule225 mgOralActavis Pharma Company2013-03-062019-07-09Canada flag
Act PregabalinCapsule25 mgOralActavis Pharma Company2013-03-062019-07-09Canada flag
Act PregabalinCapsule50 mgOralActavis Pharma Company2013-03-062019-07-09Canada flag
Act PregabalinCapsule150 mgOralActavis Pharma Company2013-03-062019-07-09Canada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Ach-pregabalinCapsule150 mgOralAccord Healthcare Inc2021-05-31Not applicableCanada flag
Ach-pregabalinCapsule50 mgOralAccord Healthcare Inc2021-05-27Not applicableCanada flag
Ach-pregabalinCapsule225 mgOralAccord Healthcare Inc2021-05-27Not applicableCanada flag
Ach-pregabalinCapsule100 mgOralAccord Healthcare IncNot applicableNot applicableCanada flag
Ach-pregabalinCapsule25 mgOralAccord Healthcare Inc2021-05-27Not applicableCanada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
BAXANT PLUS B12 150/1 MG FILM TABLET,FILM TABLET, 60 ADETPregabalin (150 mg) + Cyanocobalamin (1 mg)Tablet, film coatedOralSANTA FARMA İLAÇ SAN. A.Ş.2020-08-14Not applicableTurkey flag
BAXANT PLUS B12 225/1 MG FILM TABLET,FILM TABLET, 60 ADETPregabalin (225 mg) + Cyanocobalamin (1 mg)Tablet, film coatedOralSANTA FARMA İLAÇ SAN. A.Ş.2020-08-14Not applicableTurkey flag
BAXANT PLUS B12 25/1 MG FILM TABLET ,TABLET, 60 ADETPregabalin (25 mg) + Cyanocobalamin (1 mg)Tablet, film coatedOralSANTA FARMA İLAÇ SAN. A.Ş.2020-08-14Not applicableTurkey flag
BAXANT PLUS B12 300/1 MG FILM TABLET,TABLET, 60 ADETPregabalin (300 mg) + Cyanocobalamin (1 mg)Tablet, film coatedOralSANTA FARMA İLAÇ SAN. A.Ş.2020-08-14Not applicableTurkey flag
BAXANT PLUS B12 75/1 MG FILM TABLET ,TABLET, 60 ADETPregabalin (75 mg) + Cyanocobalamin (1 mg)Tablet, film coatedOralSANTA FARMA İLAÇ SAN. A.Ş.2020-08-14Not applicableTurkey flag


ATC Codes
N02BF02 — Pregabalin
Drug Categories
Chemical TaxonomyProvided by Classyfire
This compound belongs to the class of organic compounds known as gamma amino acids and derivatives. These are amino acids having a (-NH2) group attached to the gamma carbon atom.
Organic compounds
Super Class
Organic acids and derivatives
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Gamma amino acids and derivatives
Alternative Parents
Medium-chain fatty acids / Branched fatty acids / Amino fatty acids / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Organopnictogen compounds / Organic oxides / Monoalkylamines / Hydrocarbon derivatives
show 1 more
Aliphatic acyclic compound / Amine / Amino acid / Amino fatty acid / Branched fatty acid / Carbonyl group / Carboxylic acid / Fatty acid / Fatty acyl / Gamma amino acid or derivatives
show 11 more
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
gamma-amino acid (CHEBI:64356)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

CAS number
InChI Key
(3S)-3-(aminomethyl)-5-methylhexanoic acid


Synthesis Reference

Mark Burk, "Asymmetric synthesis of pregabalin." U.S. Patent US20030212290, issued November 13, 2003.

General References
  1. Authors unspecified: Schedules of controlled substances: placement of pregabalin into schedule V. Final rule. Fed Regist. 2005 Jul 28;70(144):43633-5. [Article]
  2. Su TZ, Feng MR, Weber ML: Mediation of highly concentrative uptake of pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J Pharmacol Exp Ther. 2005 Jun;313(3):1406-15. Epub 2005 Mar 15. [Article]
  3. Li Z, Taylor CP, Weber M, Piechan J, Prior F, Bian F, Cui M, Hoffman D, Donevan S: Pregabalin is a potent and selective ligand for alpha(2)delta-1 and alpha(2)delta-2 calcium channel subunits. Eur J Pharmacol. 2011 Sep 30;667(1-3):80-90. doi: 10.1016/j.ejphar.2011.05.054. Epub 2011 Jun 1. [Article]
  4. Bonnet U, Scherbaum N: How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol. 2017 Oct 5. pii: S0924-977X(17)30897-0. doi: 10.1016/j.euroneuro.2017.08.430. [Article]
  5. Field MJ, Oles RJ, Lewis AS, McCleary S, Hughes J, Singh L: Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. Br J Pharmacol. 1997 Aug;121(8):1513-22. [Article]
  6. Rajappa GC, Vig S, Bevanaguddaiah Y, Anadaswamy TC: Efficacy of Pregabalin as Premedication for Post-Operative Analgesia in Vaginal Hysterectomy. Anesth Pain Med. 2016 May 14;6(3):e34591. doi: 10.5812/aapm.34591. eCollection 2016 Jun. [Article]
  7. Bender G, Florian JA Jr, Bramwell S, Field MJ, Tan KK, Marshall S, DeJongh J, Bies RR, Danhof M: Pharmacokinetic-pharmacodynamic analysis of the static allodynia response to pregabalin and sildenafil in a rat model of neuropathic pain. J Pharmacol Exp Ther. 2010 Aug;334(2):599-608. doi: 10.1124/jpet.110.166074. Epub 2010 May 5. [Article]
  8. Ben-Menachem E: Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45 Suppl 6:13-8. [Article]
  9. Prompila N, Eiamart W, Jumroen Y, Sayankuldilok N, Chariyavilaskul P, Ketchat W, Wittayalertpanya S: Pharmacokinetics and bioequivalence of a pregabalin 150-mg capsule in healthy Thai subjects. Int J Clin Pharmacol Ther. 2017 Oct;55(10):811-817. doi: 10.5414/CP202954. [Article]
  10. Hong T, Han S, Lee J, Jeon S, Yim DS: Comparison of oral absorption models for pregabalin: usefulness of transit compartment model. Drug Des Devel Ther. 2016 Dec 7;10:3995-4003. eCollection 2016. [Article]
  11. Rodriguez J, Castaneda G, Munoz L: Direct determination of pregabalin in human urine by nonaqueous CE-TOF-MS. Electrophoresis. 2013 May;34(9-10):1429-36. doi: 10.1002/elps.201200564. Epub 2013 Apr 16. [Article]
  12. Randinitis EJ, Posvar EL, Alvey CW, Sedman AJ, Cook JA, Bockbrader HN: Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol. 2003 Mar;43(3):277-83. [Article]
  13. Gajraj NM: Pregabalin: its pharmacology and use in pain management. Anesth Analg. 2007 Dec;105(6):1805-15. doi: 10.1213/01.ane.0000287643.13410.5e. [Article]
  14. Zaccara G, Gangemi P, Perucca P, Specchio L: The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011 Apr;52(4):826-36. doi: 10.1111/j.1528-1167.2010.02966.x. Epub 2011 Feb 14. [Article]
  15. Toth C: Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Ther Adv Drug Saf. 2014 Feb;5(1):38-56. doi: 10.1177/2042098613505614. [Article]
  16. Takahashi Y, Nishimura T, Higuchi K, Noguchi S, Tega Y, Kurosawa T, Deguchi Y, Tomi M: Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line. Pharm Res. 2018 Oct 29;35(12):246. doi: 10.1007/s11095-018-2532-0. [Article]
  17. Stump P: [Pregabalin--profile of efficacy and tolerability in neuropathic pain]. Drugs Today (Barc). 2009 Oct;45 Suppl C:19-27. [Article]
  18. Lee DW, Lee HJ, Kim HJ, Chang SH, Park DJ: Two cases of pregabalin neurotoxicity in chronic kidney disease patients. NDT Plus. 2011 Apr;4(2):138. doi: 10.1093/ndtplus/sfq219. [Article]
  19. Wood DM, Berry DJ, Glover G, Eastwood J, Dargan PI: Significant pregabalin toxicity managed with supportive care alone. J Med Toxicol. 2010 Dec;6(4):435-7. doi: 10.1007/s13181-010-0052-3. [Article]
  20. Cross AL, Sherman Al: Pregabalin . [Article]
  21. Pfizer [Link]
  22. FDA Label Pregabalin [Link]
  23. Pfizer Medical Information - Lyrica [Link]
  24. TITCK Product Information: Pagamax Plus (pregabalin/cyanocobalamin) for oral administration [Link]
  25. FDA Approved Drug Products: LYRICA (pregabalin) Capsule/solution, for oral use [Link]
  26. DailyMed Label: LYRICA CR (pregabalin) extended-release tablets, for oral use [Link]
Human Metabolome Database
PubChem Compound
PubChem Substance
Therapeutic Targets Database
RxList Drug Page Drug Page
FDA label
Download (3.46 MB)
Download (106 KB)

Clinical Trials

Clinical Trials
4Active Not RecruitingTreatmentLumbar Disc Disease / Lumbar Spine Disc Herniation / Radiculopathy Lumbar1
4CompletedNot AvailableHealthy Volunteers (HV)1
4CompletedNot AvailableIrritable Bowel Syndrome (IBS)1
4CompletedNot AvailablePostoperative pain1
4CompletedBasic ScienceChronic Migraine / Chronic Pain / Fibromyalgia1


  • Cp pharmaceuticals cv
  • Pfizer inc
  • A-S Medication Solutions LLC
  • Bryant Ranch Prepack
  • Cardinal Health
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Goedecke GmbH
  • Innoviant Pharmacy Inc.
  • Kaiser Foundation Hospital
  • Keltman Pharmaceuticals Inc.
  • Lake Erie Medical and Surgical Supply
  • Murfreesboro Pharmaceutical Nursing Supply
  • Nucare Pharmaceuticals Inc.
  • Palmetto Pharmaceuticals Inc.
  • PD-Rx Pharmaceuticals Inc.
  • Pfizer Inc.
  • Physicians Total Care Inc.
  • Prepak Systems Inc.
  • Rebel Distributors Corp.
  • Remedy Repack
  • Resource Optimization and Innovation LLC
  • Shasun Chemicals & Drugs Ltd.
  • Southwood Pharmaceuticals
  • St Mary's Medical Park Pharmacy
  • Stat Rx Usa
  • US Pharmaceutical Group
Dosage Forms
Capsule, coatedOral50 mg
Capsule, coatedOral25 mg
Tablet, film coatedOral
Tablet, extended releaseOral165 mg
Tablet, extended releaseOral330 mg
Tablet, extended releaseOral82.5 mg
CapsuleOral150.000 MG
CapsuleOral25.000 MG
CapsuleOral50.000 MG
CapsuleOral300.000 mg
CapsuleOral75.0000 mg
Tablet, film coated150 mg
Tablet, film coated25 mg
Tablet, film coated300 mg
Tablet, film coated75 mg
SolutionOral2 g
CapsuleOral100 mg/1
CapsuleOral150 mg/1
CapsuleOral200 mg
CapsuleOral200 mg/1
CapsuleOral225 mg
CapsuleOral225 mg/1
CapsuleOral25 mg/1
CapsuleOral300 mg/1
CapsuleOral50 mg/1
CapsuleOral75 mg/1
SolutionOral2.000 g
Capsule, coatedOral5000000 mg
SolutionOral20 MG/ML
Capsule, coatedOral300 mg
Capsule, coatedOral75 mg
CapsuleOral100.00 mg
CapsuleOral200.00 mg
CapsuleOral300.00 mg
Tablet, film coated, extended releaseOral165 mg/1
Tablet, film coated, extended releaseOral330 mg/1
Tablet, film coated, extended releaseOral82.5 mg/1
Capsule, coatedOral150 mg
Capsule, coatedOral15000000 mg
Capsule, coatedOral2500000 mg
Capsule, coatedOral7500000 mg
CapsuleOral50.000 mg/Capsule
CapsuleOral75.000 mg
CapsuleOral25 mg
CapsuleOral300 mg
CapsuleOral75 mg
Tablet, effervescent100 mg
Tablet, effervescent
Tablet, effervescent200 mg
Tablet, effervescent225 mg
CapsuleOral300.0 mg
CapsuleOral150 mg
Capsule, gelatin coatedOral150 mg
Capsule, gelatin coatedOral25 mg
Capsule, gelatin coatedOral300 mg
Capsule, gelatin coatedOral75 mg
Capsule, gelatin coatedOral
Tablet, coatedOral75 mg
CapsuleOral150 mg/1mg
CapsuleOral300 mg/1mg
CapsuleOral75 mg/1mg
SolutionOral20 mg/1mL
Tablet, extended releaseOral165 mg/1
Tablet, extended releaseOral330 mg/1
Tablet, extended releaseOral82.5 mg/1
CapsuleOral125 MG
CapsuleOral175 MG
CapsuleOral250 MG
CapsuleOral275 MG
CapsuleOral100 MG
Capsule, coatedOral30000000 mg
TabletOral100 MG
TabletOral150 MG
TabletOral200 MG
TabletOral225 MG
TabletOral25 MG
TabletOral300 MG
TabletOral50 MG
TabletOral75 MG
Tablet, effervescentOral
TabletOral75.000 mg
CapsuleOral50.00 mg
CapsuleOral150.00 mg
CapsuleOral25.00 mg
CapsuleOral75.00 mg
PowderNot applicable1 kg/1kg
Injection, solution75 mg
CapsuleOral50 mg
Unit descriptionCostUnit
Lyrica 100 mg capsule2.88USD capsule
Lyrica 150 mg capsule2.88USD capsule
Lyrica 50 mg capsule2.88USD capsule
Lyrica 75 mg capsule2.88USD capsule
Lyrica 200 mg capsule2.75USD capsule
Lyrica 225 mg capsule2.75USD capsule
Lyrica 25 mg capsule2.75USD capsule
Lyrica 300 mg capsule2.75USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
US5563175No1996-10-082013-10-08US flag
CA2327285No2005-06-142019-05-10Canada flag
CA2297163No2001-11-202018-08-18Canada flag
US6001876Yes1999-12-142019-06-30US flag
USRE41920Yes2010-11-092019-06-30US flag
US6197819Yes2001-03-062019-06-30US flag
US9144559Yes2015-09-292027-05-02US flag
US8945620Yes2015-02-032027-05-02US flag
US10022447Yes2018-07-172027-05-02US flag


Experimental Properties
melting point (°C)176 - 178ºC
boiling point (°C)144 - 147 ºC
water solubilityFreely soluble
Predicted Properties
Water Solubility11.3 mg/mLALOGPS
pKa (Strongest Acidic)4.8Chemaxon
pKa (Strongest Basic)10.23Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count3Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area63.32 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity43.68 m3·mol-1Chemaxon
Polarizability18.08 Å3Chemaxon
Number of Rings0Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Human Intestinal Absorption+0.9727
Blood Brain Barrier+0.9382
Caco-2 permeable-0.6531
P-glycoprotein substrateNon-substrate0.683
P-glycoprotein inhibitor INon-inhibitor0.965
P-glycoprotein inhibitor IINon-inhibitor0.9424
Renal organic cation transporterNon-inhibitor0.9245
CYP450 2C9 substrateNon-substrate0.8758
CYP450 2D6 substrateNon-substrate0.7926
CYP450 3A4 substrateNon-substrate0.6914
CYP450 1A2 substrateNon-inhibitor0.9385
CYP450 2C9 inhibitorNon-inhibitor0.9425
CYP450 2D6 inhibitorNon-inhibitor0.9539
CYP450 2C19 inhibitorNon-inhibitor0.9629
CYP450 3A4 inhibitorNon-inhibitor0.9352
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9784
Ames testNon AMES toxic0.938
BiodegradationReady biodegradable0.8201
Rat acute toxicity1.7046 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9868
hERG inhibition (predictor II)Non-inhibitor0.8909
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)


Mass Spec (NIST)
Not Available
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-001i-9100000000-ff23b21ef03ce99e7cce
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0900000000-555454e7e8e11dab591d
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0900000000-1a52554257d7f4b1c62e
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0900000000-d48cd6eeef012787cc04
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0900000000-4b11df5208caa2e97dd2
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0a4i-0900000000-605dc241ffd3a07a9220
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01ox-0900000000-fb081cde39dde2ce89f8
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0900000000-3d95bb5278c7866658a0
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0006-0900000000-96cebf4a3610cbf02059
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-8900000000-385584fca9e88b90a95b
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-9800000000-a1c6718b087b06101b8d
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9200000000-5f291c943a1d1ae214ad
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9100000000-5283d02d98611a8c2c38
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9000000000-8797f8d2776fcdb4b6d5
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0a4i-9000000000-a9ddfcf2032ffc9f53ad
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-03dl-5900000000-69530c0930876b4307bb
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4i-0900000000-fa1d12cdb0d7012fa0c6
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0btc-1900000000-7c0eb059db6c4fb30578
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-053r-9200000000-311c1ad0e069dc95d1ee
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-0a4l-9000000000-d53b889d2c2b066cdb6d
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0a4i-9000000000-4d716280b824058bad20
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
DarkChem Lite v0.1.0
DarkChem Lite v0.1.0
DeepCCS 1.0 (2019)
DarkChem Lite v0.1.0
DarkChem Lite v0.1.0
DeepCCS 1.0 (2019)
DarkChem Lite v0.1.0
DarkChem Lite v0.1.0
DeepCCS 1.0 (2019)


Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Pharmacological action
General Function
Voltage-gated calcium channel activity
Specific Function
The alpha-2/delta subunit of voltage-dependent calcium channels regulates calcium current density and activation/inactivation kinetics of the calcium channel. Plays an important role in excitation-...
Gene Name
Uniprot ID
Uniprot Name
Voltage-dependent calcium channel subunit alpha-2/delta-1
Molecular Weight
124566.93 Da
  1. Verma V, Singh N, Singh Jaggi A: Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr Neuropharmacol. 2014 Jan;12(1):44-56. doi: 10.2174/1570159X1201140117162802. [Article]


Pharmacological action
General Function
Sodium:dicarboxylate symporter activity
Specific Function
Transports L-glutamate, L- and D-aspartate and L-cystein (PubMed:21123949). Essential for terminating the postsynaptic action of glutamate by rapidly removing released glutamate from the synaptic c...
Gene Name
Uniprot ID
Uniprot Name
Excitatory amino acid transporter 3
Molecular Weight
57099.835 Da
  1. Ryu JH, Lee PB, Kim JH, Do SH, Kim CS: Effects of pregabalin on the activity of glutamate transporter type 3. Br J Anaesth. 2012 Aug;109(2):234-9. doi: 10.1093/bja/aes120. Epub 2012 Apr 16. [Article]
Pharmacological action
General Function
Peptide antigen binding
Specific Function
Sodium-independent, high-affinity transport of large neutral amino acids such as phenylalanine, tyrosine, leucine, arginine and tryptophan, when associated with SLC3A2/4F2hc. Involved in cellular a...
Gene Name
Uniprot ID
Uniprot Name
Large neutral amino acids transporter small subunit 1
Molecular Weight
55009.62 Da
  1. Takahashi Y, Nishimura T, Higuchi K, Noguchi S, Tega Y, Kurosawa T, Deguchi Y, Tomi M: Transport of Pregabalin Via L-Type Amino Acid Transporter 1 (SLC7A5) in Human Brain Capillary Endothelial Cell Line. Pharm Res. 2018 Oct 29;35(12):246. doi: 10.1007/s11095-018-2532-0. [Article]

Drug created at June 13, 2005 13:24 / Updated at April 21, 2024 05:26